(5S,6S,9R)-5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5H-环庚[b]吡啶-9-醇 | 1373116-05-2

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: (5S,6S,9R)-5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5H-环庚[b]吡啶-9-醇
• 英文名称: (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol
• CAS: 1373116-05-2
• 化学式: C₁₆H₁₆F₂N₂O
• 分子量: 290.31
• InChiKey: LZGRTPPTGDJDKZ-ZBINZKHDSA-N

物化性质

• 沸点：
  418.7±45.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR CGRP
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011046997A1

  公开（公告）日：2011-04-21

  The disclosure generally relates to the novel compounds of formula (I), including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

  该公开涉及公式（I）的新化合物，包括药用盐，这些化合物是CGRP受体拮抗剂。该公开还涉及制药组合物和使用这些化合物治疗CGRP相关疾病的方法，包括偏头痛和其他头痛、神经源性血管舒张、神经源性炎症、热损伤、循环性休克、与绝经相关的潮红、哮喘等气道炎症性疾病以及慢性阻塞性肺疾病（COPD）。
• [EN] PROCESS FOR THE PREPARATION OF CYCLOHEPTAPYRIDINE CGRP RECEPTOR ANTAGONISTS<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ANTAGONISTES CYCLOHEPTAPYRIDINE DU RÉCEPTEUR CGRP
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012050764A1

  公开（公告）日：2012-04-19

  The disclosure generally relates to a process for the preparation of compounds of formula (I), including synthetic intermediates which are useful in the process.

  该披露通常涉及制备化合物(I)的过程，包括在该过程中有用的合成中间体。
• Process for the Preparation of Cycloheptapyridine CGRP Receptor Antagonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150361047A1

  公开（公告）日：2015-12-17

  The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process.

  本公开涉及一种制备I式化合物的方法，包括在该过程中有用的合成中间体。
• CGRP Receptor Antagonists
  申请人：Luo Guanglin

  公开号：US20110251223A1

  公开（公告）日：2011-10-13

  The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

  该披露通常涉及公式I的新化合物，包括药学上可接受的盐，这些化合物是CGRP受体拮抗剂。该披露还涉及药物组成物和使用这些化合物治疗与CGRP相关的疾病的方法，包括偏头痛和其他头痛，神经源性血管扩张，神经源性炎症，热损伤，循环休克，与绝经期相关的潮红，气道炎症性疾病，如哮喘和慢性阻塞性肺疾病（COPD）。
• PROCESS FOR THE PREPARATION OF CYCLOHEPTAPYRIDINE CGRP RECEPTOR ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150099887A1

  公开（公告）日：2015-04-09

  The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process.

  本公开涉及一种制备I式化合物的方法，包括在该过程中有用的合成中间体。